Biogen Stock: Performance in 3Q17

A look at Biogen

Headquartered in Cambridge, Massachusetts, Biogen (BIIB) is a biopharmaceutical company. It discovers, develops, and manufactures drugs for various therapeutic areas, including immunology, neurology, oncology, and rare diseases.

Biogen Stock: Performance in 3Q17

The above chart shows revenues and EPS (earnings per share) over the last eight quarters and estimates for 3Q17.

Stock performance

Biogen stock has risen ~15.4% in 3Q17, while it has risen ~31.1% year-to-date as of October 20, 2017.

Analyst recommendations

Wall Street analysts estimate that the stock has the potential to rise ~1.0% over the next 12 months. Their recommendations show a 12-month target price of $345.79 per share compared to the last price of $342.42 per share as of October 19, 2017.

There are 29 analysts tracking Biogen stock. Twenty of them recommend a “buy,” and nine recommend a “hold.” None of them have recommended a “sell.” The consensus rating for Biogen stands at 2.07, which represents a “strong buy” for long-term growth investors and a “moderate buy” for momentum investors.

Analysts’ revenue estimates

Biogen’s revenues are mainly driven by strong sales of its neurology products as well as its immuno-oncology products.

Wall Street analysts estimate revenues of $3.0 billion in 3Q17, a ~2.8% rise compared to 3Q16, and EPS of $5.73.

To divest the company-specific risks, investors can consider ETFs such as the Health Care Select Sector SPDR ETF (XLV), which holds 2.2% of its total assets in Biogen (BIIB). XLV also holds 3.2% in Bristol-Myers Squibb (BMY), 2.5% in Eli Lilly (LLY), and 2.4% in Abbott Laboratories (ABT).